CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy

NCT02013817 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphocytic Leukemia, Chronic

Interventions

DRUG: rituximab [MabThera/Rituxan]
DRUG: fludarabine
DRUG: cyclophosphamide

Sponsor

Hoffmann-La Roche